Lyell Immunopharma (NASDAQ:LYEL) Shares Gap Down to $3.01

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $3.01, but opened at $2.84. Lyell Immunopharma shares last traded at $2.58, with a volume of 191,586 shares traded.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their target price on shares of Lyell Immunopharma from $8.00 to $6.00 and set a "buy" rating on the stock in a research note on Thursday, February 29th.

Lyell Immunopharma Price Performance

The business's 50 day simple moving average is $2.24 and its 200 day simple moving average is $2.00. The company has a market capitalization of $609.84 million, a PE ratio of -2.58 and a beta of -0.55.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.01. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $4.96 million. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative return on equity of 32.67%. As a group, analysts anticipate that Lyell Immunopharma, Inc. will post -0.91 EPS for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors and hedge funds have recently made changes to their positions in LYEL. China Universal Asset Management Co. Ltd. grew its holdings in shares of Lyell Immunopharma by 352.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 29,137 shares of the company's stock valued at $57,000 after purchasing an additional 22,701 shares in the last quarter. Public Employees Retirement System of Ohio grew its holdings in shares of Lyell Immunopharma by 109.7% in the third quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company's stock valued at $40,000 after purchasing an additional 14,229 shares in the last quarter. Profund Advisors LLC grew its holdings in shares of Lyell Immunopharma by 20.0% in the third quarter. Profund Advisors LLC now owns 73,442 shares of the company's stock valued at $108,000 after purchasing an additional 12,225 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Lyell Immunopharma by 81.9% in the fourth quarter. SG Americas Securities LLC now owns 99,221 shares of the company's stock valued at $192,000 after purchasing an additional 44,686 shares in the last quarter. Finally, Citigroup Inc. grew its holdings in shares of Lyell Immunopharma by 20.0% in the third quarter. Citigroup Inc. now owns 193,739 shares of the company's stock valued at $285,000 after purchasing an additional 32,225 shares in the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.